Neoadjuvant intralesional methotrexate in squamous cell carcinoma of the lip

Intralesional Methotrexate for the Treatment of Advanced Keratinocytic Tumors: A Multi-Center Retrospective Study

“…Similarly, in 2018 Sendin and Perez described a group of patients affected by SCC of the lips, treated with two injections of MTX 50 days before surgery. The size of these tumors decreased significantly (68.18% decrease for the minor axis and 57.28% for the major) [13]. All the other studies on this matter are case reports in which MTX was again used as neoadjuvant therapy.…”

Intralesional methotrexate in dermatology: Diverse indications and practical considerations

“…All patients responded to treatment with average decreases in mean lesion diameter of 68% with a third achieving complete resolution of their tumors. No recurrence was observed following a mean follow‐up of 18.4 months 23 . Two case reports discussed the successful treatment of IL‐MTX for SCC (25 mg/ml).…”

“…No recurrence was observed following a mean follow-up of 18.4 months. 23 Two case reports discussed the successful treatment of IL-MTX for SCC (25 mg/ml). Three to four injections were required with weekly intervals over three to 4 weeks.…”

Palliative intralesional tumescent methotrexate for recurrent locally advanced periocular cutaneous squamous cell carcinoma

“…In these cases, radiotherapy, systemic chemotherapy, cetuximab, anti‐PD1 immunotherapy or electrochemotherapy (ECT) are valuable alternatives . The use of intralesional methotrexate (IL‐MTX) has mostly been described for the treatment of keratoacanthomas , in the neoadjuvant setting for management of cSCC , and in isolated curative cases of cSCC . Here we suggest tumescent intralesional MTX as a safe and inexpensive palliative treatment for locally advanced cSSC of the face.…”